Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
64.12
-1.62 (-2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corp
< Previous
1
2
3
4
5
6
Next >
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
December 10, 2023
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
November 02, 2023
From
Incyte
Via
Business Wire
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 31, 2023
From
Incyte
Via
Business Wire
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
October 27, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
October 18, 2023
From
Incyte
Via
Business Wire
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
October 16, 2023
From
Incyte
Via
Business Wire
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
October 13, 2023
From
Incyte
Via
Business Wire
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
October 13, 2023
From
Incyte
Via
Business Wire
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
October 11, 2023
From
Incyte
Via
Business Wire
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
October 11, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
October 11, 2023
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 10, 2023
From
Incyte
Via
Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 29, 2023
From
Incyte
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Incyte to Present at Upcoming Investor Conferences
August 22, 2023
From
Incyte
Via
Business Wire
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 01, 2023
From
Incyte Corporation
Via
Business Wire
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 31, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
July 11, 2023
From
Incyte
Via
Business Wire
Incyte to Report Second Quarter Financial Results
July 11, 2023
From
Incyte
Via
Business Wire
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 25, 2023
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.